Biotech entity
Of the tracked stories, 3 of 3 also mention Terns Pharmaceuticals, the most common co-covered peer. Across a 151-day span, the pace is roughly 0.1 stories per week. The busiest single day carried 2. Coverage clusters in acquisition, which accounts for 2 of those 3, with the remainder spread across 1 other category.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention Terns Pharmaceuticals, the most common co-covered peer. Across a 151-day span, the pace is roughly 0.1 stories per week. The busiest single day carried 2. Coverage clusters in acquisition, which accounts for 2 of those 3, with the remainder spread across 1 other category. Source depth averages 2 original sources per story, versus 3.7 across the same-window beat baseline. At 7.3, the average consequence score sits above the same-window beat average of 6.2. We currently track 3 Biotech stories that mention Keytruda, published between March 25, 2026 and August 22, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 321 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Keytruda. Shared-story counts are live from our verified record — not editorial picks.
Keytruda Patent Expiry
Merck faces biosimilar competition for its top-selling immunotherapy drug.
TERN-701 Data Readout
Key clinical milestones for the leukemia candidate are expected to drive valuation.
Argus raises Merck price target
Argus lifts its Merck target from $130 to $145 with a Buy rating, citing pipeline depth and clinical progress.
Merck discloses Evaxion stake
Merck reports holding 1,214,126 shares of Evaxion A/S in a regulatory filing.
Expected Closing
The deal is anticipated to close following regulatory approvals and Terns shareholder vote.
Acquisition Announced
Merck and Terns Pharmaceuticals sign a definitive agreement for a $6.7B buyout.
Merck exercises EVX-B3 option
Merck decides to in-license Evaxion's discovery-stage AI-derived vaccine candidate EVX-B3 against an undisclosed bacterial pathogen.
Prometheus Acquisition
Merck buys Prometheus Biosciences for $10.8 billion to bolster its immunology pipeline.
Acceleron Acquisition
Merck acquires Acceleron Pharma for $11.5 billion to expand in cardiovascular disease.
Merck's option to in-license Evaxion's EVX-B3 vaccine candidate, combined with a 1.21 million-share stake, provides early validation for the biotech's AI antigen discovery platform. For biotech investors, the deal is a discovery-stage bet with long clinical timelines.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a promising allosteric BCR-ABL inhibitor for leukemia. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its blockbuster drug, Keytruda.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion in cash, a strategic move to diversify its oncology pipeline. The deal centers on Terns' promising leukemia candidate, TERN-701, as Merck prepares for the 2028 patent expiration of its blockbuster immunotherapy, Keytruda.
Keytruda is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
